StockGuru Shines its Spotlight on Total Nutraceutical Solutions, Inc. (OTCBB: TNUS) Massachusetts General Hospital to Assess the Efficacy of ERGO-D2(TM) as a Potential Treatment for Parkinson’s Disease Patients — August 18, 2011

StockGuru Shines its Spotlight on  Total Nutraceutical Solutions, Inc. (OTCBB: TNUS) Massachusetts General Hospital to Assess the Efficacy of ERGO-D2(TM) as a Potential Treatment for Parkinson’s Disease Patients — August 18, 2011

Dallas, Texas (August 18, 2011) – StockGuru Shines its Spotlight on  Total Nutraceutical Solutions, Inc. (TNS) (OTCBB:TNUS) announced yesterday that it has entered into a research agreement with Dr. Jack Rogers, Ph.D., Associate Professor of Psychiatry and Neuroscience at Harvard Medical School and Director of the Neurochemistry Laboratory at Massachusetts General Hospital, to evaluate the therapeutic and prophylactic potential of Ergo-D2™ as a dietary therapy or as a palliative therapy for Parkinson’s disease patients.  The Company closed on August 17, 2011, at $0.06, up twenty percent, trading in a fifty two week range of $0.25 – 0.026.

Parkinson’s disease (PD) is a chronic progressive movement disorder characterized by shaking and difficulty with walking, movement and coordination and affects over one million people in the United States. The cause is unknown and there is presently no cure. PD involves the malfunction and death of vital nerve cells in the brain that produce dopamine, a chemical that sends messages to the part of the brain that controls movement and coordination. The amount of dopamine in the brain decreases with the progression of PD until a person is unable to control normal movement.

One of the hallmark signs of this debilitating disease is an aggregation of the protein alpha-synuclein which is found not only in the mid-brain but also in the brain stem and the olfactory bulb. These areas of the brain correlate to non-motor functions such as sense of smell and sleep regulation which could explain the non-motor symptoms experienced by some people with PD before any motor signs of the disease appear. Alpha-synuclein has been identified as a genetic risk factor for PD and is a logical target for therapies such as the TNS dietary supplement Ergo-D2™, that have the potential to inhibit synthesis and accumulation as well as lower the toxicity of this protein.

Dr. Rogers will be working with Dr. Catherine Cahill, Ph.D to measure in vivo the efficacy of Ergo-D2™ in repressing alpha-synuclein translation and promoting the survival and viability of dopaminergic neurons using the transgenic mouse model for PD. “The potential ability of the potent antioxidant Ergo-D2™ to target and control alpha-synuclein is most exciting,” stated Dr. Jack Rogers. “There is a definite scarcity of available therapies for PD and my lab is pleased to be part of this important solution.”

Ergo-D2™ is a mushroom-based functional food ingredient containing L-Ergothioneine and Vitamin D2. L-Ergothioneine (Ergo) is made in few organisms, notably filamentous fungi, and is an amino acid whose chemistry differs from conventional sulfur-containing antioxidants such as glutathione and lipoic acid. Although L-Ergothioneine cannot be made in human cells, it is a powerful antioxidant that is present in some tissues at high levels and can only be absorbed from the diet. In humans, Ergo is taken up from the gut and concentrated in tissues by a specific genetically encoded transport protein called The Ergothioneine Transporter. TNS announced on March 10, 2010 that the company acquired the exclusive world-wide rights to this transporter from the University of Cologne, Cologne, Germany. The license comprises the patent application entitled “Identification of Ergothioneine Transporter and Therapeutic Uses Thereof.” TNS has also filed a series of provisional use patents covering the application of L-Ergothioneine, Vitamin D2 and/or Ergo-D2™ in neuroinflammatory disease states associated with free radicals and oxidative stress, such as Alzheimer’s disease, Parkinson’s disease, post-traumatic stress disorder (PTSD), depression and other comorbid chronic inflammatory conditions.

About Total Nutraceutical Solutions, Inc.

TNS is a global leader in whole food biotechnology that identifies, scientifically validates, and commercializes functional ingredients and other products that address multi-billion dollar markets for organic health, beauty and agriculture. The company’s growing portfolio of intellectual property includes extraction, enhancement, and uses for some of the most powerful anti-oxidants and bionutrients occurring in nature.

The Total Nutraceutical Solutions, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8060

Any statements contained in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties including, but not limited to, the risks associated with the transaction described in this press release, and other risks identified in the filings by Total Nutraceutical Solutions (TNS), Inc. with the Securities and Exchange Commission. Further information on risks faced by TNS are detailed in the Form 10-K for the year ended December 31, 2010 and in its subsequent Quarterly Reports on Form 10-Q. These filings are or will become available on a website maintained by the Securities and Exchange Commission at http://www.sec.gov. The information contained in this press release is accurate as of the date indicated. Actual results, events or performance may differ materially. TNS does not undertake any obligation to publicly release the result of any revision to these forward- looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Visit TotalNutraceutical.com or contact the Company at 509-427-5132 or email info@totalnutraceutical.com.

To view this StockGuru Spotlight, please visit: http://www.stockguru.com/category/latest-spotlights/

To get free alerts on this and other similar stocks, please register here:

http://www.stockguru.com/?page_id=250

What is the StockGuru Spotlight?

Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.

StockGuru looks for potential break-out candidates in The StockGuru Spotlight.  Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage.  There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below.   StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.

To feature a company in The StockGuru Spotlight please contact the Publisher at publisher@stockguru.com.  If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile.  Please contact the StockGuru Publisher John Pentony at this email address:  john@stockguru.com.

Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions.  SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.

This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage.  When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present.  Additionally SG also discloses any anticipated compensation in the future.  Compensation is typically in cash.  Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.

John Pentony, Publisher, Stockguru.com

Tel: +1 469 252 3031

e-mail: john@stockguru.com